Analysts Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Target Price at $11.50

Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) have been assigned an average recommendation of “Buy” from the eight ratings firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and three have issued a strong buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $11.50.

Several research analysts have issued reports on ACRS shares. Oppenheimer began coverage on shares of Aclaris Therapeutics in a report on Thursday, April 16th. They set an “outperform” rating and a $10.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Wednesday, June 24th. Piper Sandler boosted their price target on shares of Aclaris Therapeutics from $7.00 to $11.00 and gave the company an “overweight” rating in a report on Tuesday, May 5th. UBS Group set a $10.00 price target on shares of Aclaris Therapeutics in a research report on Thursday, April 16th. Finally, Guggenheim assumed coverage on shares of Aclaris Therapeutics in a research note on Tuesday, May 5th. They set a “buy” rating and a $12.00 price objective on the stock.

Insider Transactions at Aclaris Therapeutics

In other Aclaris Therapeutics news, major shareholder Braden Michael Leonard sold 300,000 shares of the stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $4.53, for a total transaction of $1,359,000.00. Following the sale, the insider owned 13,950,000 shares of the company’s stock, valued at approximately $63,193,500. This trade represents a 2.11% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 4.80% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. XTX Topco Ltd purchased a new position in Aclaris Therapeutics in the second quarter valued at about $34,000. R Squared Ltd bought a new position in Aclaris Therapeutics in the fourth quarter worth about $37,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Aclaris Therapeutics during the second quarter valued at about $48,000. BNP Paribas Financial Markets lifted its position in shares of Aclaris Therapeutics by 59.0% during the third quarter. BNP Paribas Financial Markets now owns 26,667 shares of the biotechnology company’s stock valued at $51,000 after buying an additional 9,894 shares during the last quarter. Finally, CIBC Asset Management Inc bought a new stake in shares of Aclaris Therapeutics in the 4th quarter valued at about $52,000. 98.34% of the stock is owned by institutional investors.

Aclaris Therapeutics Price Performance

Shares of NASDAQ ACRS opened at $5.68 on Friday. Aclaris Therapeutics has a twelve month low of $1.46 and a twelve month high of $5.85. The firm has a market cap of $793.27 million, a PE ratio of -10.14 and a beta of 0.76. The business has a fifty day simple moving average of $4.84 and a two-hundred day simple moving average of $4.04.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. The business had revenue of $2.00 million for the quarter, compared to the consensus estimate of $1.32 million. Aclaris Therapeutics had a negative return on equity of 55.89% and a negative net margin of 832.58%. On average, research analysts expect that Aclaris Therapeutics will post -0.65 earnings per share for the current year.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.